Last reviewed · How we verify
Hydroxide Potassium
Hydroxide Potassium, marketed by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not disclosed. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Hydroxide Potassium |
|---|---|
| Sponsor | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- Point-of-care Tests for Vaginal Discharge in Nepal (NA)
- Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution (NA)
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
- Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke (PHASE4)
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (PHASE3)
- 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |